Alkermes (NASDAQ:ALKS - Get Free Report) had its price target decreased by equities research analysts at UBS Group from $38.00 to $33.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a "neutral" rating on the stock. UBS Group's price objective indicates a potential upside of 3.84% from the stock's previous close.
ALKS has been the topic of several other research reports. The Goldman Sachs Group lifted their price objective on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 14th. StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. HC Wainwright reaffirmed a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Finally, Royal Bank of Canada started coverage on shares of Alkermes in a research report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price target for the company. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $38.33.
Check Out Our Latest Stock Report on Alkermes
Alkermes Trading Up 3.9 %
NASDAQ:ALKS traded up $1.20 during trading hours on Monday, hitting $31.78. 3,455,782 shares of the company traded hands, compared to its average volume of 1,767,889. Alkermes has a twelve month low of $22.90 and a twelve month high of $36.45. The firm has a 50-day moving average of $31.33 and a 200 day moving average of $30.46. The stock has a market capitalization of $5.24 billion, a price-to-earnings ratio of 14.65, a P/E/G ratio of 2.20 and a beta of 0.39.
Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The company had revenue of $306.51 million for the quarter, compared to analyst estimates of $307.53 million. During the same period in the prior year, the company posted $0.43 EPS. The firm's quarterly revenue was down 12.6% on a year-over-year basis. Equities research analysts predict that Alkermes will post 1.31 earnings per share for the current fiscal year.
Insider Transactions at Alkermes
In related news, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now directly owns 57,875 shares of the company's stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 4.40% of the company's stock.
Institutional Investors Weigh In On Alkermes
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC bought a new stake in shares of Alkermes during the fourth quarter valued at approximately $25,000. EverSource Wealth Advisors LLC lifted its holdings in Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock worth $47,000 after buying an additional 842 shares in the last quarter. Blue Trust Inc. boosted its position in Alkermes by 2,231.5% in the 4th quarter. Blue Trust Inc. now owns 1,702 shares of the company's stock valued at $49,000 after buying an additional 1,629 shares during the last quarter. USA Financial Formulas acquired a new stake in shares of Alkermes in the 1st quarter valued at $49,000. Finally, Fifth Third Bancorp increased its stake in shares of Alkermes by 54.4% in the 1st quarter. Fifth Third Bancorp now owns 1,479 shares of the company's stock valued at $49,000 after buying an additional 521 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.
About Alkermes
(
Get Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Read More
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
